ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177
GARCHING / MUNICH, Germany and INDIANAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) — ITM Isotope Technologies…
News
ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177
Garching / Munich, Germany and Indianapolis, IN, USA, July 31, 2023 – ITM Isotope Technologies…
ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177
GARCHING / MUNICH, Germany and INDIANAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) — ITM Isotope Technologies…
Blue Water Biotech and Knipper Health Join Forces to Distribute Samples for ENTADFI® and ZONTIVITY® to Physicians
CINCINNATI, July 31, 2023 (GLOBE NEWSWIRE) — Blue Water Biotech, Inc. (“Blue Water” or the…
Blue Water Biotech and Knipper Health Join Forces to Distribute Samples for ENTADFI® and ZONTIVITY® to Physicians
CINCINNATI, July 31, 2023 (GLOBE NEWSWIRE) — Blue Water Biotech, Inc. (“Blue Water” or the…
COMPASS Pathways plc to announce second quarter 2023 financial results on August 3, 2023
LONDON, July 31, 2023 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company…
COMPASS Pathways plc to announce second quarter 2023 financial results on August 3, 2023
LONDON, July 31, 2023 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company…
New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
– Results Confirm that Trilaciclib Reduces Single and Multilineage Grade ≥3 Myelosuppressive Hematologic Adverse Events…
New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
– Results Confirm that Trilaciclib Reduces Single and Multilineage Grade ≥3 Myelosuppressive Hematologic Adverse Events…
Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences
Transaction and reduction in operating expenses enhance Mustang’s cash position WORCESTER, Mass., July 31, 2023…
Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences
Transaction and reduction in operating expenses enhance Mustang’s cash position WORCESTER, Mass., July 31, 2023…
PharmAla Files Patent for Novel MDXX Molecule PharmAla-1
Patent Filing Follows Year of Preclinical Research, Academic Publication VANCOUVER, British Columbia, July 31, 2023…
PharmAla Files Patent for Novel MDXX Molecule PharmAla-1
Patent Filing Follows Year of Preclinical Research, Academic Publication VANCOUVER, British Columbia, July 31, 2023…
TG Therapeutics to Host Conference Call on Second Quarter 2023 Financial Results and Business Update
Conference call to be held Tuesday, August 1, 2023, at 8:30 AM ET NEW YORK,…
TG Therapeutics to Host Conference Call on Second Quarter 2023 Financial Results and Business Update
Conference call to be held Tuesday, August 1, 2023, at 8:30 AM ET NEW YORK,…
T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirements
LEXINGTON, Mass., July 31, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in…
T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirements
LEXINGTON, Mass., July 31, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in…
Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr
Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q…
Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr
Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q…
Crinetics Hosting Key Opinion Leader Webinar to Discuss the Current Treatment Landscape and Unmet Need in Acromegaly
Webinar Being Held on August 8, 2023 at 12:00 p.m. Eastern Time SAN DIEGO, July…